Literature DB >> 10954044

Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase.

Y Niwa1, N Nagata, M Oka, T Toyoshima, H Akiyoshi, T Wada, Y Nakaya.   

Abstract

Human chymase selectively converts big endothelin (ET)-1 to 31-amino-acid-length ET-1 [ET-1(1-31)]. In this study we examined effect of ET-1(1-31) on endothelial function. ET-1(1-31) evoked contraction in a concentration-dependent manner at > 10(-8) M, which was about 10 times weaker than that of conventional ET-1 [ET-1(1-21)]. BQ485, an ETA receptor antagonist, completely abolished ET-1(1-31)-induced contraction, but BQ788, an ETB receptor antagonist, slightly enhanced it, suggesting that ET-1(1-31) relaxes artery via endothelium. On endothelial cells, ET-1(1-21) and ET-1(1-31) increased [Ca2+]i and produced NO, both of which were significantly inhibited by BQ788 and not by BQ485. These results indicate that ET-1(1-31) increased [Ca2+]i and produced NO in endothelial cells through ETB receptor similarly with ET-1(1-21), although slight difference in effect on smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954044     DOI: 10.1016/s0024-3205(00)00700-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs.

Authors:  Jean-Claude Honoré; Mirco Plante; Ghassan Bkaily; Giles A Rae; Pedro D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 3.  Endothelial cell-cardiomyocyte crosstalk in heart development and disease.

Authors:  Andrea Colliva; Luca Braga; Mauro Giacca; Serena Zacchigna
Journal:  J Physiol       Date:  2019-03-27       Impact factor: 5.182

4.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.